Clinical trials · New York, NY
Prostate cancer clinical trials in New York
We’re tracking 160 recruiting prostate cancer studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT07181161RecruitingPhase 1/Phase 2
Testing a new drug for metastatic prostate cancer
This trial tests an investigational drug (AZD0516) alone or with other treatments in men with prostate cancer that has spread to other parts of the body and is no longer responding to hormone therapy. It aims to see if the drug can help control the cancer.
New York, New YorkAges 18–130 - NCT07184957Recruiting
Cryotherapy for localized prostate cancer: a data study
This study tracks outcomes for men who choose cryotherapy (freezing cancer cells) to treat prostate cancer that hasn't spread. It helps doctors understand how well this treatment works.
New York, New YorkAges 40–85 - NCT06542757Recruiting
Focused radiation to main prostate tumor using MRI guidance
This trial tests a stronger, more focused radiation dose to the main tumor inside the prostate using MRI guidance. It aims to improve control of intermediate-risk prostate cancer while possibly reducing side effects.
New York, New YorkAges 18 years+ - NCT06533644RecruitingPhase 2
SYNC-T therapy study for advanced prostate cancer
This trial tests a new treatment called SYNC-T Therapy (SV-102) for men with metastatic castration-resistant prostate cancer that has progressed after other treatments. The therapy is given directly into a tumor to help your immune system fight the cancer.
New York, New YorkAges 18 years+ - NCT05519449RecruitingPhase 1
Testing a PSMA-targeting treatment for advanced prostate cancer
This Phase 1 trial tests JANX007 in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite standard hormone treatment). It aims to find a safe dose and see whether the treatment can shrink tumors or slow progression.
New York, New YorkAges 18–100 - NCT06815354Recruiting
Cancer treatment response study for metastatic prostate cancer
This study uses special scans to see how well the drug Pluvicto is working in men with metastatic prostate cancer. You would have two PET scans, one before starting treatment and one after 12 weeks, to check your cancer's response.
New York, New YorkAges 18 years+ - NCT05743621RecruitingPhase 1
First TVB-2640 and enzalutamide for metastatic prostate cancer
This Phase 1 trial tests a new medicine (TVB-2640) combined with enzalutamide in men with prostate cancer that has spread and is no longer responding to hormone treatment. It aims to find a safe dose and see how well the treatment can work against the cancer.
New York, New YorkAges 18 years+ - NCT05948657Recruiting
PSMA PET-CT scan for men on prostate cancer surveillance
This study checks whether a special prostate scan called PSMA PET-CT (along with standard monitoring scans) can help guide care while you are on “active surveillance” instead of immediate treatment. It may help doctors track low-risk prostate cancer changes more accurately over time.
New York, New YorkAges 18 years+ - NCT03067051RecruitingPhase 1/Phase 2
Test of a prostate cancer light-activated treatment device
This study tests the safety and early effectiveness of the SpectraCure P18 system, which uses light-activated medicine to treat prostate cancer that has come back locally after radiation. It may help some people avoid or delay more invasive treatment, while researchers carefully watch side effects.
New York, New YorkAges 18 years+ - NCT05351424Recruiting
Spanish-language cancer care support for breast or prostate radiation
This study tests an educational and communication support program to help Spanish-speaking people stay on track with treatment when they’re getting radiation for non-spread (non-metastatic) breast or prostate cancer. It may help by improving understanding through interpreter-supported visits.
New York, New YorkAges 18 years+ - NCT06582017RecruitingPhase 1
Study of QXL138AM for advanced solid tumors and multiple myeloma
This trial tests an investigational drug called QXL138AM for people with advanced solid tumors or multiple myeloma that has not responded to standard treatments. The goal is to see if the drug is safe and effective.
New York, New YorkAges 18 years+ - NCT03678025RecruitingPhase 3
Standard treatment for metastatic prostate cancer, with or without local treatment
This Phase 3 trial studies whether using the usual medicines for metastatic prostate cancer, plus a definitive local treatment to the prostate, improves outcomes. It may help determine if treating the prostate directly can benefit people whose cancer has not worsened after initial hormone-based treatment.
New York, New YorkAges 18 years+ - NCT07052214RecruitingPhase 3
PSMA PET plus MRI to find prostate cancer
This trial tests if combining a PSMA PET scan with an MRI can better detect clinically significant prostate cancer than MRI alone. It may help men who have not had a prostate biopsy before and have certain risk factors.
New York, New YorkAges 18 years+ - NCT06632977RecruitingPhase 2
Matching targeted treatments to your prostate cancer's genetics
This trial is testing whether matching your cancer's specific genetic changes to a targeted treatment can help control metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. You may receive a drug, a radioactive treatment, or a combination based on your tumor's molecular profile.
New York, New YorkAges 18 years+ - NCT07028853RecruitingPhase 3
New drug combo for advanced prostate cancer
This study tests whether adding the investigational drug mevrometostat to the standard treatment enzalutamide works better than enzalutamide alone for men with prostate cancer that has spread to other parts of the body (metastatic castration-sensitive prostate cancer). You may benefit if you haven't yet received chemotherapy or similar strong treatments for this stage of cancer.
New York, New YorkAges 18 years+ - NCT07335796RecruitingPhase 2
Testing a new drug combination before prostate cancer surgery
This trial tests a new drug (BMS-986365) combined with another hormone therapy (degarelix) before radical prostatectomy for high-risk prostate cancer. The goal is to see if this combination helps lower cancer activity before surgery.
New York, New YorkAges 18 years+ - NCT06764485RecruitingPhase 3
Comparing a new drug to standard therapy for advanced prostate cancer
This trial tests a new medicine (BMS-986365) against the doctor's choice of standard therapy for men with metastatic castration-resistant prostate cancer. It aims to see which treatment works better and is safer.
New York, New YorkAges 18 years+ - NCT07189403RecruitingPhase 1
Study of DS9051b for adrenal cancer and prostate cancer
This trial tests a new drug called DS9051b in people with advanced adrenal cancer or metastatic prostate cancer that has stopped responding to other treatments. It aims to see if the drug is safe and works against these cancers.
New York, New YorkAges 18 years+ - NCT07184970Recruiting
Detecting prostate cancer return after HIFU with advanced scans
This trial uses a special PET/MRI scan to check if prostate cancer has come back after high-intensity focused ultrasound (HIFU) treatment. It aims to find any remaining cancer early so doctors can plan next steps.
New York, New YorkAges 40–95 - NCT06545942RecruitingPhase 1
Studying MOMA-313 for advanced or metastatic solid tumors
This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.
New York, New YorkAges 18 years+ - NCT07548164RecruitingPhase 3
Radiation Boost Methods for Intermediate-Risk Prostate Cancer
This trial compares two different ways to give focused radiation to the prostate in men with intermediate-risk prostate cancer. The goal is to see which approach works better and is safer for patients.
New York, New YorkAges Any age - NCT06095089RecruitingPhase 1
Study of two drugs for advanced prostate cancer
This trial tests a new combination of two study drugs for people with advanced prostate cancer that has spread or is no longer responding to hormone therapy. The goal is to see if the combination is safe and works against the cancer.
New York, New YorkAges 18 years+ - NCT06991556RecruitingPhase 2
Testing JSB462 plus abiraterone for advanced prostate cancer
This trial tests a new drug called JSB462 combined with abiraterone in men with prostate cancer that has spread to other parts of the body and is still responding to hormone therapy. The goal is to see if this combination works better than current treatments.
New York, New YorkAges 18 years+ - NCT07142967Recruiting
MR-Linac radiotherapy for prostate cancer that returned after earlier radiation
This trial tests if a special MRI-guided radiotherapy machine (MR-Linac) can safely treat prostate cancer that has come back after previous radiation therapy. It may help men who have limited options and want to avoid more invasive treatments.
New York, New YorkAges 18 years+
Hear when a new Prostate cancer trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Prostate cancer trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting prostate cancer studies listed above.
- Weill Cornell Medicine · 8 studies
- NYU Langone Health · 7 studies
- Memorial Sloan Kettering Cancer Center · 6 studies
- Montefiore Medical Center · 4 studies
- Memorial Sloan Kettering Bergen · 3 studies
- Memorial Sloan Kettering Nassau · 3 studies
- Columbia University Irving Medical Center · 2 studies
- Hackensack University Medical Center · 2 studies
What taking part in a prostate cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting prostate cancer studies in New York.
Common questions
- Are there prostate cancer clinical trials near New York?
- Yes. We're currently tracking 160 recruiting prostate cancer studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a prostate cancer study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a prostate cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New prostate cancer studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.